President Donald Trump’s decision to suspend the work of the United States Agency for International Development (USAID) could ...
Johns Hopkins University said it would eliminate more than 2,000 jobs after the Trump administration rescinded funding for ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.
Recent cancellation of federally funded grants results in significant changes for the university's global health activities ...
In a ceremony held last month, the 2024 Louisa Gross Horwitz Prize was awarded to Wesley Sundquist, PhD, Leo T. and Barbara K ...
Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Invite the Ukrainian president to the heartland of America. Show him and the world that we categorically denounce the treatment he received.
Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback